Selumetinib in Children with Inoperable Plexiform Neurofibromas
Top Cited Papers
- 18 March 2020
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 382 (15), 1430-1442
- https://doi.org/10.1056/nejmoa1912735
Abstract
No approved therapies exist for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1.Keywords
Funding Information
- Neurofibromatosis Therapeutics Acceleration Program
- AstraZeneca
- National Cancer Institute Intramural Research Program
- Developmental and Hyperactive Ras Tumor (DHART) Spore (U54 CA196519-04)
This publication has 38 references indexed in Scilit:
- MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumorsJCI Insight, 2012
- Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Frequency and Associated Clinical DeficitsThe Journal of Pediatrics, 2011
- Construction of the eight-item patient-reported outcomes measurement information system pediatric physical function scales: built using item response theoryJournal of Clinical Epidemiology, 2011
- Neurofibromatosis Type 1 RevisitedPEDIATRICS, 2009
- Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1Neuro-Oncology, 2008
- NF1 plexiform neurofibroma growth rate by volumetric MRINeurology, 2007
- Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scaleEuropean journal of pain, 2004
- Interpretation of Changes in Health-related Quality of LifeMedical Care, 2003
- The Neurofibromatosis Type 1 GeneAnnual Review of Neuroscience, 1993
- Studies with pain rating scales.Annals Of The Rheumatic Diseases, 1978